Restoring Inflammatory Mediator Balance After Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2018 Jul 7

PMID 29977152

Citations 20

Authors

Georgia Nascimento Saraiva

Natalia Fonseca do Rosario

Thalia Medeiros

Paulo Emilio Correa Leite

Gilmar de Souza Lacerda

Thais Guarana de Andrade

Elzinandes Leal de Azeredo

Petronela Ancuta

Jorge Reis Almeida

Analucia Rampazzo Xavier

Andrea Alice Silva

Affiliations

Soon will be listed here.

Abstract

This study aimed at analyzing circulating levels of inflammatory and profibrogenic cytokines in patients with hepatitis C virus (HCV) chronic infection undergoing therapy with direct-acting antiviral agents (DAA) and correlating these immune biomarkers with liver disease status. We studied 88 Brazilian monoinfected chronic hepatitis C patients receiving interferon- (IFN-) free sofosbuvir-based regimens for 12 or 24 weeks, followed-up before therapy initiation and three months after the end of treatment. Liver disease was determined by transient elastography, in addition to APRI and FIB-4 indexes. Analysis of 30 immune mediators was carried out by multiplex or enzymatic immunoassays. Sustained virological response rate was 98.9%. Serum levels of cytokines were increased in HCV-infected patients when compared to control group. CCL-2, CCL-3, CCL-4, CXCL-8, CXCL-10, IL-1, IL-15, IFN-, IL-4, IL-10, TGF-, FGFb, and PAI-1 decreased significantly after antiviral therapy, reaching values similar to noninfected controls. TGF- and suPAR levels were associated with fibrosis/cirrhosis. Also, we observed amelioration in hepatic parameters after DAA treatment. Together, our results suggest that viral control induced by IFN-free DAA therapy restores inflammatory mediators in association with improvement in liver function.

Citing Articles

Changes in Vascular Endothelial Growth Factor and Development of Hepatocellular Carcinoma in Direct-Acting Antiviral Drugs (DAAs)-Treated Hepatitis C Virus (HCV) Patients.

Hassan A, Orabi H, Abdel-Gawad M, Mohamed O, Sawy S, Abdelmeguid M Cureus. 2025; 16(12):e75982.

PMID: 39830567 PMC: 11742266. DOI: 10.7759/cureus.75982.

CXCL10, SCGN, and H2BC5 as Potential Key Genes Regulated by HCV Infection.

Yildirim C, Yay F, Imre A, Soysal O, Yildirim H Genes (Basel). 2025; 15(12.

PMID: 39766770 PMC: 11675613. DOI: 10.3390/genes15121502.

Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?.

Ragazzo T, Zitelli P, Mazo D, Oliveira C, Carrilho F, Pessoa M Clinics (Sao Paulo). 2024; 79:100381.

PMID: 38733689 PMC: 11103362. DOI: 10.1016/j.clinsp.2024.100381.

Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy.

Hearps A, Vootukuru N, Ebrahimnezhaddarzi S, Harney B, Boo I, Nguyen L Front Immunol. 2024; 15:1352440.

PMID: 38420130 PMC: 10899672. DOI: 10.3389/fimmu.2024.1352440.

Serum omentin-1 is correlated with the severity of liver disease in patients with chronic hepatitis C.

Peschel G, Weigand K, Grimm J, Muller M, Buechler C World J Hepatol. 2024; 15(12):1315-1324.

PMID: 38223417 PMC: 10784814. DOI: 10.4254/wjh.v15.i12.1315.

References

Paquissi F . Immunity and Fibrogenesis: The Role of Th17/IL-17 Axis in HBV and HCV-induced Chronic Hepatitis and Progression to Cirrhosis. Front Immunol. 2017; 8:1195. PMC: 5626935. DOI: 10.3389/fimmu.2017.01195. View

Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M . Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005; 128(2):343-50. DOI: 10.1053/j.gastro.2004.11.018. View

da Luz C, Boyles M, Falagan-Lotsch P, Pereira M, Tutumi H, de Oliveira Santos E . Poly-lactic acid nanoparticles (PLA-NP) promote physiological modifications in lung epithelial cells and are internalized by clathrin-coated pits and lipid rafts. J Nanobiotechnology. 2017; 15(1):11. PMC: 5282631. DOI: 10.1186/s12951-016-0238-1. View

Jung M, Shin E . Regulatory T Cells in Hepatitis B and C Virus Infections. Immune Netw. 2016; 16(6):330-336. PMC: 5195842. DOI: 10.4110/in.2016.16.6.330. View

Burchill M, Roby J, Crochet N, Wind-Rotolo M, Stone A, Edwards M . Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy. PLoS One. 2017; 12(10):e0186213. PMC: 5645093. DOI: 10.1371/journal.pone.0186213. View

Duffy D, Mamdouh R, Laird M, Soneson C, Le Fouler L, El-Daly M . The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis. Hepatology. 2014; 59(4):1273-82. DOI: 10.1002/hep.26901. View

Menezes E, Coelho-Dos-Reis J, Cardoso L, Lopes-Ribeiro A, Jonathan-Goncalves J, Porto Goncalves M . Strategies for serum chemokine/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases. Antiviral Res. 2017; 141:19-28. DOI: 10.1016/j.antiviral.2017.02.001. View

Ogasawara N, Kobayashi M, Akuta N, Kominami Y, Fujiyama S, Kawamura Y . Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. J Med Virol. 2017; 90(2):313-319. DOI: 10.1002/jmv.24950. View

Kumthip K, Maneekarn N . The role of HCV proteins on treatment outcomes. Virol J. 2015; 12:217. PMC: 4678629. DOI: 10.1186/s12985-015-0450-x. View

10.

Chalupa P, Davidova A, Beran O, Arientova S, Bostik P, Kapla J . Effect of antiviral treatment of chronic hepatitis C on the frequency of regulatory T cells, T-cell activation, and serum levels of TGF-beta. APMIS. 2016; 124(8):711-8. DOI: 10.1111/apm.12561. View

11.

Hengst J, Falk C, Schlaphoff V, Deterding K, Manns M, Cornberg M . Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. J Infect Dis. 2016; 214(12):1965-1974. DOI: 10.1093/infdis/jiw457. View

12.

Zimmermann H, Koch A, Seidler S, Trautwein C, Tacke F . Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2011; 32(3):500-9. DOI: 10.1111/j.1478-3231.2011.02665.x. View

13.

Majumdar A, Kitson M, Roberts S . Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016; 43(12):1276-92. DOI: 10.1111/apt.13633. View

14.

Wong M, Chen S . Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol. 2014; 13(1):11-35. PMC: 4712384. DOI: 10.1038/cmi.2014.127. View

15.

Berres M, Schlosser B, Berg T, Trautwein C, Wasmuth H . Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol. 2011; 46(4):334-8. DOI: 10.1097/MCG.0b013e31822da19d. View

16.

Fierro N, Gonzalez-Aldaco K, Torres-Valadez R, Trujillo-Trujillo M, Roman S, Trujillo-Ochoa J . Spontaneous hepatitis C viral clearance and hepatitis C chronic infection are associated with distinct cytokine profiles in Mexican patients. Mem Inst Oswaldo Cruz. 2015; 110(2):267-71. PMC: 4489461. DOI: 10.1590/0074-02760140377. View

17.

Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M . DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS One. 2016; 11(12):e0167934. PMC: 5172554. DOI: 10.1371/journal.pone.0167934. View

18.

Tao Y, Wang M, Chen E, Tang H . Liver Regeneration: Analysis of the Main Relevant Signaling Molecules. Mediators Inflamm. 2017; 2017:4256352. PMC: 5602614. DOI: 10.1155/2017/4256352. View

19.

Sterling R, Lissen E, Clumeck N, Sola R, Correa M, Montaner J . Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6):1317-25. DOI: 10.1002/hep.21178. View

20.

Wai C, Greenson J, Fontana R, Kalbfleisch J, Marrero J, Conjeevaram H . A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2):518-26. DOI: 10.1053/jhep.2003.50346. View